We invite you to attend the 2017 Cancer Therapeutics & Partnering Summit, to be held on September 28-29, 2017 in San Diego, CA. This summit includes three parallel conferences focused on both the research, and business perspectives in oncology.
This summit will continue to be a premier event for translational researchers, preclinical scientists and managers, and those carrying out early phase clinical trials working to identify and exploit advances in the field of oncology in order to deliver products with a meaningful clinical impact. In addition, industry leaders from big pharma and various biotech/pharmaceutical companies, including business/corporate development executives, licensing executives, global alliance, and venture capitalists, will all be present to explore potential collaborations and learn about relevant issues in oncology.
Focus areas include cancer diagnostics, cancer immunotherapy, as well as partnering and deal-making in oncology. Discussion topics include emerging targets, therapeutic strategies, next generation sequencing in cancer diagnosis, progress in cancer immunotherapy, combination strategies in immuno-oncology, advancements in technology, as well as business development trends, markets, partnership opportunities, and access to capital market.
Both cutting-edge researchers and those who guide its commercial development will be on-hand to share their knowledge
and insights as to how therapeutic cancer targets are identified, and how this research translates into meaningful therapeutics
that benefit patients living with cancer!
Joint Plenary Sessions:
I. Opening Keynote Session – Historical Perspective & Current State of the Industry
II. Round Table Discussions
III. Ready, Set, Grow – New Company/Technology Pitch Competition
IV. Award Ceremony & Closing Keynote Session – Predictions for future
Complementary & Companion Diagnostics in Oncology
I. Technologies and Biomarkers
II. Case Studies for Development and Commercialization
I. Precision Medicine and Immunomodulatory Antibodies
II. Combination Immunotherapy and Novel Targets
Oncology Partnering & Deal-Making
I. What sells in Oncology – New Targets, Models, Assays, etc.
II. Industry Partnering with Academic Groups & CROs to Advance Research
III. Oncology Perspectives from Venture Capital & Public Markets
IV. Technology Transfer & Licensing: Challenges & Opportunities
We hope to see you there!
The 2017 Advisory Committee
|2017 Program Director|
|Saikat Nandi, Cold Spring Harbor Laboratories|
|2017 Advisory Board Members|
|Tullia Bruno, University of Pittsburgh|
|Angela Thomas, Edinburgh Haemophilia Centre|
|Kamala Maddali, Cancer Genetics Incorporated|
|Alan Epstein, University of Southern California|
|Charles Theuer, TRACON Pharmaceuticals|
|Satish Medicetty, GTCbio|
Reaction Biology Corp. is a CRO that specializes in epigenetic and kinase HTS and profiling services. RBC's radioisotope based assays feature the largest collection of kinase & epigenetic targets available to the industry, including more than 559 kinases, 100+ reader domains, >30 methyltransferases, all HDACs and SIRTs, demethylases and more. RBC also produces high quality epigenetic proteins that are available for purchase.
The IvyGene test is a blood test that uses advanced DNA sequencing methods to detect the DNA methylation pattern of circulating tumor DNA (ctDNA) in blood samples in order to both confirm the presence of malignant cancer and to identify the cancer tissue of origin.
ACEA Biosciences Inc. produces cutting-edge cell analysis instruments. Our xCELLigence® RTCA systems enable label-free, real-time monitoring of cell proliferation, cell morphology, cell adhesion, cytotoxicity and cell invasion/migration. Our NovoCyte® benchtop flow cytometers include up to 17-parameter detection, volumetric cell counting, and autosampling at accessible price points. www.aceabio.com
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Using novel epigenetic technology, Epiontis provides precise and reproducible immunomonitoring services for clinical trials. The epigenetic PCR tests are based on in-house developed and IP protected markers specific for immune cell types (Treg, Th17, overall Tcells, etc.). Frozen whole blood or tissue can be used, permitting easy storage and logistics.